Dilian Francisca Toro Torres

Dr Toro is a physician. She graduated from the Universidad Libre Cali, Colombia. Specialist in Internal Medicine and Rheumatology of the Federal University of Rio de Janeiro, Brazil and in Health Administration of the Universidad del Valle, Cali, Colombia. She was Mayor (1992-1994) of the Municipality of Guacarí, Valle del Cauca; she served as Health Secretary of the Department and Health Consultant of the Inter-American Development Bank (IDB). In 2002 she was elected Senator.  In 2006, she served as President of the Congress and in 2010, as President of the Constitutional Seventh Permanent Commission. Advocate for health issues and author of the Reform to Law 100, the Human Resource on Health Act, the Anti-Smoking Law, Non-Violence against Women Law and the Orphan Diseases Law. She was a panelist at the UN General Assembly. She has received several distinctions as the Order of Congress of the Republic for her work as president of the Senate; José Vicente Huertas Order of Merit of the Colombian Cancer Institute and the Award for Leadership and Excellence in Smoke-Free Environments policies from The Global Smoke Free Partnership. She was Governor of the Valle del Cauca for the period 2016-2019. During her period, she was elected best Governor in categories 1 and 2, distinction awarded by the Colombia Leader Foundation to the Best Mayors and Governors for the period 2016-2019.

Posters

Call for poster presentation at the 1st Pan American Congress of Autism, Fragile X Syndrome and Neurodevelopmental Disorders:

Within the framework of the activities of the 1st Pan American Congress of Autism, Fragile X Syndrome and Neurodevelopmental Disorders, the call to participate in the presentation of scientific posters is open

1. About the presentation of posters:

The Congress will take place in Cartagena de Indias, Colombia, during the first half of 2021.

The purpose of the Congress is to update professionals on basic concepts of neurodevelopmental disorders, as well as comorbidities, diagnosis, treatments and new pharmacological, therapeutic, technological, genetic and clinical advances. With the presentation of the poster format, the aim is to enhance scientific communication and dissemination of research projects.

The presentation of posters shall have only the in-person modality:

Posters will be exhibited from the morning of the first day of the Congress to the afternoon of the last day. At least one of the authors must be registered and ready to present the poster, answer questions and enter into dialogue with the participants, in a period of two hours that will be communicated to the authors.

Proposals will have to go through an evaluation process, which will be based on a summary/abstract. The evaluation will be carried out by a Scientific Evaluation Committee. Under no circumstances a poster proposal may be accepted if it cannot be presented in person by the authors themselves during the Congress.

2. Selection process:

The summary/abstract of the poster (up to 300 words) must be accompanied by the following information:

1. Poster title

2. Full name of the author(s).

3. The name of the author submitting must be underlined

4. Institution or entity to which the authors are affiliated to

5. Email and contact phone number

6. Keywords (4-6)

7. Specify the area: scientific or clinical

The deadline for submission of poster summaries is still TBD. Abstracts must be sent via email to copa.axt@gmail.com

The Scientific Committee will evaluate the proposals and communicate to the authors, by e-mail, their acceptance or rejection decision.

The criteria to be evaluated are: Consistency and relevance with the contents of the Congress

Once the poster summary is accepted, the authors can proceed to print the poster. The printed version must have the following dimensions: 122 cm (high) by 92 (wide), and will be mounted in the exhibition space defined on Thursday, April 16th (before the official opening).

3. Recognition and awards:

The posters will be evaluated by the scientific evaluation committee during the two-hour period assigned for presentation. Once the poster presentation session is completed, the 3 most outstanding works will be announced. The winners will receive a certificate of recognition and the reimbursement of the total registration cost.

Extended versions of the presented work will be published by Revista de Neurología – Spain

Scientific Evaluation Committee:

1. Bibiana M Restrepo, MD (USA)

2. Rosa D Rodriguez, MD (USA)

3. Denise Medici, PhD (Spain)

4. Leticia Boada, PhD (Spain)

5. Stephen Noctor, PhD (USA)

6. César Payán, MD, PhD (Colombia)

Brett Dufour, PhD

Dr. Dufour is a postdoctoral researcher at the University of California, Davis in the laboratory of Dr. Veronica Martinez-Cerdeno.  He earned his PhD in Behavioral Neuroscience at Oregon Health & Science University (OHSU) and his MS in Animal Sciences from Purdue University. The focus of his research is to characterize the neuropathological mechanisms that underlie neurodevelopmental and neurodegenerative disorders, and to use these findings to develop targeted genetic and pharmacological therapies. His MS thesis research focused on abnormal repetitive behaviors in animals, with an emphasis in stereotypic and compulsive behaviors. He has worked with a variety of different species, including human and non-human primates as well as a variety of rodent species. Currently he is investigating whether there are alterations in the neural circuitry that regulates social behavior in fragile X syndrome and autism utilizing human postmortem brain tissue.

Amaya Miquelajauregui, PhD

Dr. Miquelajauregui is an assistant professor at the Institute of Neurobiology of the University of Puerto Rico at the Medical Sciences Campus. Research in Dr. Miquelajauregui’s lab aims to understand brain development processes from embryonic to postnatal stages and to characterize alterations caused by genetic and environmental factors using rodent models of neurodevelopmental disorders. She also currently conducts a longitudinal study that tracks infants under 3 months to 18 months of age trying to describe the development trajectories of high-risk populations using cognitive and physiological measures.

Ángel E. Tovar y Romo, PhD

Dr. Angel Eugenio Tovar y Romo is an associate professor at the Department of Psychology at the Universidad Nacional Autonoma de Mexico (UNAM) and belongs to Mexico’s National System of Researchers. He obtained his doctorate in psychology at UNAM and later completed a postdoctoral fellowship at Lancaster University, United Kingdom in Dr. Gert Westermann’s Laboratory of cognitive science. His research focuses on understanding cognitive development, pathway to the modeling and computational simulation of processes of perception, categorization, memory, and their impact on language. He studies populations with typical and atypical development, particularly populations with Down syndrome and autism spectrum disorders. Some of his works have been published in journals such as Cognition and Developmental Science and presented in forums such as the Conference of the Cognitive Science Society, a society of which he is also a member.

Bibiana M Restrepo, MD

Doctor Restrepo is a specialist in neurodevelopmental disorders. She graduated from Tufts University in Boston. She obtained her pediatrician degree from the University of Texas and graduated as a physician at the Universidad Tecnologica de Pereira, Colombia. She is currently an associate clinical professor in the Department of Pediatrics at the University of California Davis School of Medicine and director of ECHO Autism at the University of California Davis MIND Institute

Dr. Restrepo’s work focuses on early detection, diagnosis and management of neurodevelopmental problems, specifically autism spectrum disorder. She is particularly passionate about strengthening collaboration between professionals and therapists in addition to participating in the teaching of the new generation of doctors and leaders in the field of neuro-disabilities.

César Payán, MD, PhD

Geneticist and Doctor of Biomedical Sciences. He is a professor of molecular biology and embryology at the Universidad del Rosario in Bogota, Colombia. His research focuses on understanding the causal molecular pathways of the development of neurodegenerative diseases such as Parkinson’s Disease and some phenotypes of the fragile X syndrome. In a broader way he is interested in understanding the molecular mechanisms of aging.

Flora Tassone, PhD

Dr. Tassone received her diploma as a Bachelor in Biology from the University of Rome and a PhD in molecular biology from the Catholic University of Rome (Italy) in 1992 for her studies on Down syndrome. During her postdoctoral fellowship, first at the Eleanor Roosevelt Institute in Denver, Colorado, and then at the University of Colorado Health Science Center, she continued to work on identifying genes involved in Down syndrome and began to focus on the molecular basis that leads to fragile X syndrome and autism spectrum disorders. In 2000, she moved to the University of California, Davis, and focused her research on neurodevelopmental disorders, including FXS and associated disorders, ASD and deletion 22q11.2 syndrome. She is a professor in the Department of Biochemistry and Molecular Medicine at the University of California, Davis School of Medicine and a researcher at the MIND Institute. Her experience is in regulating transcriptional and translational genes, particularly the FMR1 gene.

Jenniffer Villarreal, child neuropsychologist

Dr. Villarreal is a psychologist. She has a master’s in child neuropsychology. She has dedicated her career to the care of neurodevelopmental disorders. She is the founder and director of Neurodesarrollo Quito, a private institution dedicated to offer continuing education in the area of neurodevelopment to professionals in Ecuador and to offer interventions to patients regardless of their economic status without limitations. Dr. Villarreal wants her model to serve as an example for the private sector and eventually the entire population of Ecuador can have access to quality interventions.

Julián Ramírez-Cheyne, MD, PhD

Dr. Ramírez-Cheyne is an assistant professor at the Universidad del Valle in the subjects of genetics, embryology and congenital malformations. Geneticist and scientific director of the Center for Orphan Diseases of the Hospital Universitario del Valle; active member of MACOS research group; and academic advisor to the orphan diseases team of the Public Health Office in Cali, Colombia.

Dr Ramirez-Cheyne earned his medical, master’s in biomedical sciences with an emphasis on embryology and PhD in biomedical sciences with an emphasis on medical genetics degrees at the Universidad del Valle in Cali, Colombia. Among his recognitions, he has obtained a scholarship/internship as A Young Researcher Colciencias and a doctoral fellowship from the Teaching Seed program of the Universidad del Valle.